Ashish Sethi

Dr. Ashish Sethi

Scattering Team, Australian Synchrotron, Melbourne, Victoria, Australia
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKlára Kirsch
Klára Kirsch
AZAndrás Zeke
András Zeke
OTOrsolya Tőke
Orsolya Tőke
PSPeter Sok
Peter Sok
ASAshish Sethi
Ashish Sethi
ARAttila Reményi
Attila Reményi
Transcription factor phosphorylation at specific sites often activates gene expression, but how environmental cues quantitatively control transcription is not well-understood. Activating protein 1 transcription factors are phosphorylated by mitogen-activated protein kinases (MAPK) in their transactivation domains (TAD) at so-called phosphoswitches, which are a hallmark in response to growth factors, cytokines or stress. We show that the ATF2 TAD is controlled by functionally distinct signaling pathways (JNK and p38) through structurally different MAPK binding sites. Moreover, JNK mediated phosphorylation at an evolutionarily more recent site diminishes p38 binding and made the phosphoswitch differently sensitive to JNK and p38 in vertebrates. Structures of MAPK-TAD complexes and mechanistic modeling of ATF2 TAD phosphorylation in cells suggest that kinase binding motifs and phosphorylation sites line up to maximize MAPK based co-regulation. This study shows how the activity of an ancient transcription controlling phosphoswitch became dependent on the relative flux of upstream signals.

1 May 2018 in Journal of Molecular Biology
Verified
Journal Article
Open access
ENEstella Anne Newcombe
Estella Anne Newcombe
KRKiersten M. Ruff
Kiersten M. Ruff
ASAshish Sethi
Ashish Sethi
AOAngelique R. Ormsby
Angelique R. Ormsby
YRYasmin M. Ramdzan
Yasmin M. Ramdzan
DHDanny M. Hatters
Danny M. Hatters
Soluble huntingtin exon 1 (Httex1) with expanded polyglutamine (polyQ) engenders neurotoxicity in Huntington's disease. To uncover the physical basis of this toxicity, we performed structural studies of soluble Httex1 for wild-type and mutant polyQ lengths. Nuclear magnetic resonance experiments show evidence for conformational rigidity across the polyQ region. In contrast, hydrogen-deuterium exchange shows absence of backbone amide protection, suggesting negligible persistence of hydrogen bonds. The seemingly conflicting results are explained by all-atom simulations, which show that Httex1 adopts tadpole-like structures with a globular head encompassing the N-terminal amphipathic and polyQ regions and the tail encompassing the C-terminal proline-rich region. The surface area of the globular domain increases monotonically with polyQ length. This stimulates sharp increases in gain-of-function interactions in cells for expanded polyQ, and one of these interactions is with the stress-granule protein Fus. Our results highlight plausible connections between Httex1 structure and routes to neurotoxicity.

18 April 2016 in Nature Communications
Verified
Journal Article
Open access
ASAshish Sethi
Ashish Sethi
SBShoni Bruell
Shoni Bruell
NPNitin Patil
Nitin Patil
MHMohammed Akhter Hossain
Mohammed Akhter Hossain
DSDaniel Scott
Daniel Scott
PGPaul Gooley
Paul Gooley
H2 relaxin activates the relaxin family peptide receptor-1 (RXFP1), a class A G-protein coupled receptor, by a poorly understood mechanism. The ectodomain of RXFP1 comprises an N-terminal LDLa module, essential for activation, tethered to a leucine-rich repeat (LRR) domain by a 32-residue linker. H2 relaxin is hypothesized to bind with high affinity to the LRR domain enabling the LDLa module to bind and activate the transmembrane domain of RXFP1. Here we define a relaxin-binding site on the LDLa-LRR linker, essential for the high affinity of H2 relaxin for the ectodomain of RXFP1, and show that residues within the LDLa-LRR linker are critical for receptor activation. We propose H2 relaxin binds and stabilizes a helical conformation of the LDLa-LRR linker that positions residues of both the linker and the LDLa module to bind the transmembrane domain and activate RXFP1.

1 November 2019 in Cell Reports
Verified
Journal Article
Open access
AHAlamgir Hossain
Alamgir Hossain
FLFlorence Larrous
Florence Larrous
SRStephen M. Rawlinson
Stephen M. Rawlinson
JZJingyu Zhan
Jingyu Zhan
ASAshish Sethi
Ashish Sethi
PGPaul Gooley
Paul Gooley
To evade immunity, many viruses express interferon antagonists that target STAT transcription factors as a major component of pathogenesis. Because of a lack of direct structural data, these interfaces are poorly understood. We report the structural analysis of full-length STAT1 binding to an interferon antagonist of a human pathogenic virus. The interface revealed by transferred cross-saturation NMR is complex, involving multiple regions in both the viral and cellular proteins. Molecular mapping analysis, combined with biophysical characterization and in vitro/in vivo functional assays, indicates that the interface is significant in disease caused by a pathogenic field-strain lyssavirus, with critical roles for contacts between the STAT1 coiled-coil/DNA-binding domains and specific regions within the viral protein. These data elucidate the potentially complex nature of IFN antagonist/STAT interactions, and the spatial relationship of protein interfaces that mediate immune evasion and replication, providing insight into how viruses can regulate these essential functions via single multifunctional proteins.

9 March 2022 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
ASAshish Sethi
Ashish Sethi
CHChristopher R. Horne
Christopher R. Horne
CFCheree Fitzgibbon
Cheree Fitzgibbon
KWKaryn Wilde
Karyn Wilde
KDKatherine A. Davies
Katherine A. Davies
JMJames M. Murphy
James M. Murphy

1 January 2019 in iScience
Verified
Journal Article
Open access
BHBradley L. Hoare
Bradley L. Hoare
SBShoni Bruell
Shoni Bruell
ASAshish Sethi
Ashish Sethi
PGPaul R. Gooley
Paul R. Gooley
MLMichael J. Lew
Michael J. Lew
Ross BathgateRoss Bathgate
Ross Bathgate
The peptide hormone H2 relaxin has demonstrated promise as a therapeutic, but mimetic development has been hindered by the poorly understood relaxin receptor RXFP1 activation mechanism. H2 relaxin is hypothesized to bind to two distinct ECD sites, which reorientates the N-terminal LDLa module to activate the transmembrane domain. Here we provide evidence for this model in live cells by measuring bioluminescence resonance energy transfer (BRET) between nanoluciferase-tagged RXFP1 constructs and fluorescently labeled H2 relaxin (NanoBRET). Additionally, we validate these results using the related RXFP2 receptor and chimeras with an inserted RXFP1-binding domain utilizing NanoBRET and nuclear magnetic resonance studies on recombinant proteins. We therefore provide evidence for the multi-component molecular mechanism of H2 relaxin binding to RXFP1 on the full-length receptor in cells. Also, we show the utility of NanoBRET real-time binding kinetics to reveal subtle binding complexities, which may be overlooked in traditional equilibrium binding assays.